[1]
|
Towheed, T., Maxwell, L., Anastassiades, T.P., Shea, B., Houpt, J.B., Welch, V., Hochberg, M.C. and Wells, G.A. (2005) Glucosamine therapy for treating osteoarthritis. Cochrane Database of Systematic Reviews, 2.
|
[2]
|
Setnikar, I. and Rovati, L.C. (2001) Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung, 51(9), 699-725.
|
[3]
|
Persiani, S., Roda, E., Rovati, L.C., Locatelli, M., Giacovelli, G. and Roda, A. (2005) Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis and Cartilage, 13(12), 1041-1049.
|
[4]
|
Persiani, S., Rotini, R., Trisolino, G., Rovati, L.C., Locatelli, M., Paganini, D., Antonioli, D. and Roda, A. (2007) Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulfate at therapeutic dose. Osteoarthritis and Cartilage, 15(7), 764-772.
|
[5]
|
Simoens, S. (2009) Economic evaluation of glucosamine sulphate treatment in knee osteoarthritis. ISPOR’s 12th Annual European Congress, 24-27 October, Paris.
|
[6]
|
National Institute for Health and Clinical Excellence. (2009) Osteoarthritis: The care and management of osteoarthritis in adults: NICE clinical guideline 59. http://www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdf
|
[7]
|
Ku, L.J.E. and Biddle, A. (2009) Cost-effectiveness of glucosamine sulfate treatment among elderly knee osteoarthritis patients. 7th World IHEA Congress on Health Economics, Beijing.
|